High Lipoprotein(a) Symptoms: Causes, Signs & What to Do
Lipoprotein(a) [Lp(a)] is almost entirely genetically determined, cannot be lowered by diet or exercise, and doubles the risk of premature heart attack and stroke -- yet most people are never tested. This page covers what high Lp(a) means, why it's dangerous, and what can actually be done about it.
Lipoprotein(a) [Lp(a)] is a modified form of LDL with an additional protein called apolipoprotein(a) [apo(a)] attached. It is primarily determined by genetics — specifically, the number of “kringle IV type 2” repeats in the LPA gene — and is largely unaffected by diet, exercise, or most lipid-lowering medications. High Lp(a) is one of the most common hereditary cardiovascular risk factors: approximately 20-25% of the global population has Lp(a) above 50 mg/dL, the widely used high-risk threshold. Most of them are unaware because Lp(a) is not routinely included in standard lipid panels. See the Lipoprotein(a) biomarker overview for measurement details and the difference between mg/dL and nmol/L units.
What High Lipoprotein(a) Means
Lp(a) drives cardiovascular disease through two distinct mechanisms:
- LDL-like atherogenicity — Lp(a) is taken up by artery walls, oxidized, and incorporated into atherosclerotic plaques, similar to LDL but with higher affinity for vessel walls
- Procoagulant activity — the apo(a) protein structurally resembles plasminogen and competitively inhibits plasminogen binding, impairing fibrinolysis (the body’s clot-dissolving system); this explains why high Lp(a) is associated with clot-triggered events
Additionally, Lp(a) promotes calcific aortic valve disease — the protein accumulates in the valve leaflets, accelerating calcification — a unique risk not shared by LDL.
Symptoms of High Lipoprotein(a)
High Lp(a) produces no direct symptoms. All clinical consequences are from its long-term effects:
- Premature heart attack — Lp(a) roughly doubles the risk of myocardial infarction; events can occur in people in their 30s-40s with no other traditional risk factors
- Ischemic stroke — from both atherosclerotic disease and from the procoagulant mechanism
- Peripheral arterial disease — claudication and non-healing wounds from lower limb atherosclerosis
- Recurrent cardiovascular events — high Lp(a) is associated with worse outcomes even in people already on statin therapy, because Lp(a) is not reduced by statins
- Calcific aortic stenosis — progressive heart valve narrowing, presenting in later decades as exertional dyspnea, angina, and syncope
Family history clues that suggest high Lp(a):
- A first-degree relative with a heart attack before age 55 in men or 65 in women
- A family history of aortic valve replacement or aortic stenosis
- Persistently elevated cardiovascular risk despite optimal LDL and lifestyle
What Causes High Lipoprotein(a)
- Genetics (primary cause) — Lp(a) levels are 80-90% heritable; the LPA gene determines apo(a) isoform size; shorter isoforms are produced more rapidly and associate with higher Lp(a) levels
- Autosomal codominant inheritance — both alleles are expressed; a child of a parent with high Lp(a) has a 50% chance of inheriting the high-Lp(a) allele
- Post-menopause — estrogen suppresses Lp(a) production; after menopause, Lp(a) often rises by 20-30%
- Kidney disease — reduced renal clearance and increased hepatic production raise Lp(a)
- Hypothyroidism — thyroid hormone affects Lp(a) metabolism; hypothyroidism can raise Lp(a)
What does NOT significantly lower Lp(a): statins, fibrates, diet modification, aerobic exercise.
Normal Lipoprotein(a) Levels
| Category | Lp(a) Level (mg/dL) | Risk Interpretation | |---|---|---| | Optimal | Below 30 | Low risk | | Borderline elevated | 30-50 | Moderate risk signal | | High (treatment consideration) | Above 50 | Elevated cardiovascular risk | | Very high | Above 100 | High independent risk |
Note: Lp(a) can also be reported in nmol/L. The 50 mg/dL threshold corresponds to approximately 100-125 nmol/L, but the conversion varies by assay.
When to See Your Care Team
Book a 1:1 consultation with a licensed care team lead for Lp(a) above 50 mg/dL, particularly with a family history of premature cardiovascular disease. Since Lp(a) itself cannot be lowered by lifestyle, the focus shifts to aggressively reducing all other modifiable risk factors: target LDL below 70 mg/dL, control blood pressure and blood glucose, eliminate smoking. PCSK9 inhibitors modestly lower Lp(a) by 20-30%. Dedicated RNA therapies targeting Lp(a) specifically are in late-stage clinical trials.
Frequently Asked Questions
Can exercise or diet lower Lp(a)?
No — not meaningfully. Lp(a) is genetically determined and does not respond to diet, aerobic exercise, or most lipid-lowering therapies. This is a core difference from LDL. A Mediterranean diet, weight loss, or statin use will lower LDL significantly but leave Lp(a) essentially unchanged. Screening and aggressive management of all other cardiovascular risk factors is the current approach.
Do statins make Lp(a) worse?
Some studies show statins can paradoxically raise Lp(a) by 10-20%. The clinical significance is debated — statins still substantially reduce cardiovascular risk in high-Lp(a) patients by lowering LDL, and the net benefit is clear for individuals with combined elevated LDL and Lp(a).
Should family members be tested if I have high Lp(a)?
Yes. Because Lp(a) is codominant and highly heritable, first-degree relatives (parents, siblings, children) have a 50% probability of inheriting the same high-Lp(a) allele. The European Atherosclerosis Society recommends cascade testing of family members when an index case with Lp(a) above 50 mg/dL is identified.
What new treatments are coming?
Two RNA-targeting therapies — pelacarsen (antisense oligonucleotide) and olpasiran (siRNA) — have shown 80-90% reductions in Lp(a) in Phase 2 and Phase 3 trials. Outcome data for cardiovascular event reduction are expected from the HORIZON and OCEAN(a) trials. These would be the first approved therapies to specifically lower Lp(a).
References
- MedlinePlus: Lipoprotein(a)
- NIH: Lipoprotein(a) and cardiovascular risk
- Cleveland Clinic: High lipoprotein(a)
